Summary of Onxeo’s Liquidity Contract with Kepler Cheuvreux

July 3, 2020 – 6:00 pm CEST   Pursuant to the liquidity contract granted to Kepler Cheuvreux regarding Onxeo shares, […]

• 2020
• Financials and Corporate
• Press releases

Tags: Financials & Corporate

07/03/2020

Onxeo Confirms in Preclinical Studies the Profile of OX401, a Potent PARP Agonist with Strong Anti-Tumor Activity and Immunological Properties

Paris (France), June 25, 2020 – 7.00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

• 2020
• OX401
• Press releases

Tags: OX401

06/25/2020

New AsiDNA™ e-Poster Now Online at AACR Virtual Meeting 2020

Preclinical Data Confirm the Ability of AsiDNA™ to Reverse Cancer Resistance to PARPi by Preventing Regrowth of Death-Tolerant Cells   […]

• 2020
• AsiDNA™
• Press releases

Tags: AsiDNA™

06/22/2020

Onxeo: report on the Extraordinary General Meeting of June 19, 2020

Paris (France), June 19, 2020 – 5.45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

• 2020
• Press releases

Tags: Financials & Corporate

06/19/2020

Boursoroma – Judith Greciet, Onxeo : «AsiDNA could open a new paradigm in cancer treatment»

  Read the interview  

• 2020
• AsiDNA™
• Media

Tags: AsiDNA™

06/17/2020

Onxeo offre 10,7% de son capital à Invus – Biotech Finances

(French only) Regards croisés : Interviews of Judith Greciet, CEO of Onxeo, and Mr Nicolas Trebouta, representing Financière de la […]

• 2020
• Financials and Corporate
• Media
• Uncategorized

Tags: Financials & Corporate

06/15/2020

BFM Business Intégrale Bourse : Onxeo, Company of the Day

  Interview of Judith Greciet, CEO of Onxeo, following the entry into the capital of Invus, a long-term renowned investor […]

• 2020
• AsiDNA™
• Financials and Corporate
• Media
• Uncategorized

Tags: AsiDNA™, Financials & Corporate

06/10/2020

Onxeo announces a capital increase of €7.3 million by private placement to Invus and Financière de la Montagne, the Company’s historical shareholder

The funds raised will accelerate the development of Onxeo’s programs, and extend its cash runway into Q1 2022                 Paris […]

• 2020
• Financial operations
• Press releases

Tags: Financials & Corporate

06/09/2020

Onxeo announces that the Shareholders’ Meeting of May 29, 2020 has approved all ordinary resolutions

The Extraordinary General Meeting will be held on June 19, 2020 on the second call   Paris (France), May 29, […]

• 2020
• Financials and Corporate
• Press releases

Tags: Financials & Corporate

05/29/2020

Onxeo Announces Approval of the REVocan Study By Regulatory Authorities

The REVocan study aims to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian […]

• 2020
• AsiDNA™
• Press releases

Tags: AsiDNA™